With the rapid development of biotechnology, the field of antibody-drug discovery has witnessed unprecedented innovation. The traditional hybridoma technology, as the classic method of antibody discovery, has been widely used by the research community since it was first proposed by Kohler and Milstein in 1975. However, with the emergence of new technologies, such as the Hypercell  platform from Bioelectronica Holdings Inc., the path of antibody drug discovery is undergoing profound changes.

​​

​

Traditional hybridoma technology: a classic and proven cornerstone

​​

Traditional hybridoma technology, also known as lymphocyte hybridoma technology or monoclonal antibody technology, is based on somatic cell fusion technology. This technique is based on the fusion of B-lymphocytes from immunized animals with myeloma cells to form hybridoma cells that can continuously secrete specific monoclonal antibodies. This approach solves the problem that immune lymphocytes cannot be propagated for long periods of time in vitro and makes it possible to prepare highly pure monoclonal antibodies. Because of its mature technical system and broad application value, hybridoma technology has occupied a critical position in antibody drug research and development.

​​

​​​

​

​

​

​

​

​

​

​

The Hypercell   Platform: An Innovative Leap in Digitization and Automation

​​

In contrast to traditional hybridoma technology, the Hypercell  platform represents a digital and automated innovation in antibody drug discovery. The platform utilizes computer vision, data science, and lensless imaging for rapid and accurate single-cell sorting. The high-speed automation enables single-cell sorting assays to be performed with high-speed total processing power, dramatically improving the efficiency of the antibody discovery and development process.

​

• Efficiency and Accuracy: The Hypercell  platform significantly improves the efficiency and accuracy of single-cell sorting through digitalization and automation. Compared to the cumbersome manual screening process in traditional hybridoma technology, the Hypercell  platform can identify positive B-cell clonal cells more quickly and accurately, thus accelerating antibody drug discovery and development.

​

• Throughput and Scalability: While traditional hybridoma technologies face challenges in handling large numbers of samples, the Hypercell  platform offers the advantages of high throughput and impressive scalability. This feature not only enables the platform to cope with the demands of large-scale antibody screening but also provides strong support for rapid antibody drug development, reassuring you of its adaptability.

​​

• Innovation and Flexibility: The Hypercell  platform is not only technologically innovative but also highly flexible in its application. Through continuous algorithm optimization and system upgrades, the platform is able to adapt to the needs of different research projects, providing more possibilities for antibody drug development. This flexibility opens up exciting potential for your research projects.

​​​

​

​

​

​

​

​

​

​

​

​​

​

​

In addition, we are very much looking forward to meeting you at the 76th Association for Diagnostics & Laboratory Medicine (ADLM), which will be held from July 28 to August 1, 2024, in Chicago, USA, at booth #4955. We hope to meet with you, share more experiences about the Hypercell   platform, and explore together the infinite possibilities of antibody drug discovery and development!